Our mission is to address the unmet medical needs of millions affected by complex genetic conditions, through the discovery of novel biomarkers and drug targets, ending their diagnostic and therapeutic odyssey.
The power of AI merged with genomic data analysis unlocks the blueprint of life enabling us to diagnose earlier and tailoring drugs for effective treatment.
Every individual, regardless of the rarity of their condition, should have access to timely diagnosis and effective treatments, ensuring a life of dignity, potential, and hope.
We work for 350 million rare disease patients, 70% among these are children suffering from 7000+ diseases. Out of these only 5% have FDA approved treatment.
VGen23 – A comprehensive genomic analysis solution that accelerates clinical diagnostics for labs.
VGen23 – Provides disease insights and discover novel targets for pharmaceutical companies.
A dynamic database for labs to reclassify and interpret Variants of Uncertain Significance (VUS). It collects, curates, presents, and updates itself, everyday!
An AI powered rare disease diagnosis platform that assists healthcare providers make informed decisions.
Biotech company, Vgenomics raises seed investment from Mumbai Angels & others
Vgenomics and Meril Genomics Join Hands to Advance Precision Medicine in India
Tear-Based Biomarker Identified for early detection of keratoconus
Genomics and AI set to transform rare disease diagnosis and therapeutics
Genomics and Health Equity: Making Precision Medicine Accessible for All
Vgenomics, Dr. Shroff Charity Eye Hospital partner to validate biomarker for early Keratoconus detection
Vgenomics exhibiting at TechSparks 2025, India’s top startup tech event
Vgenomics recognised as one of the Tech30 Startups of the Year at YourStory’s TechSparks 2025
Vgenomics selected in the top 30 startups powering India’s next innovation wave
Dr. Rahila Sardar, CEO of Vgenomics, shares her insights on Precision oncology in India: Pg 12
Dr. Rahila Sardar, CEO of Vgenomics, sheds light on how genomics, AI, and stronger collaboration can accelerate rare disease care: Pg 10
Read More
